EMA Authorised: Alimta (pemetrexed) — Eli Lilly Nederland B.V.

View source ↗

Summary

EMA has authorised the marketing of Alimta (pemetrexed) for malignant mesothelioma and non-small cell lung cancer in the EU. The marketing authorization holder …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Status: Authorised. Therapeutic area: Mesothelioma;Carcinoma, Non-Small-Cell Lung. MAH: Eli Lilly Nederland B.V.. Decision date: 16/01/2026